Oxaliplatin, an anticancer agent that affects both Na+ and K+ channels in frog peripheral myelinated axons

General Physiology and Biophysics

Volumn 25, Issue 3, 2006, Pages 263-276

  Benoit, Evelyne ^a   Brienza, S ^b   Dubois, J M ^a  

^a CNRS   (France)

^b Debioclinic ^*  (France)

Author keywords

Anticancer agent; Oxaliplatin; Peripheral myelinated axons; Potassium and sodium channels; Voltage clamp technique

Indexed keywords

ANTINEOPLASTIC AGENT; OXALIPLATIN; POTASSIUM CHANNEL; SODIUM CHANNEL;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FROG; MALE; MYELINATED NERVE; NERVE FIBER MEMBRANE POTENTIAL; NERVE MEMBRANE; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; POTASSIUM CONDUCTANCE; POTASSIUM CURRENT; RANVIER NODE; SODIUM CONDUCTANCE; SODIUM CURRENT; STEADY STATE; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; AXONS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MEMBRANE POTENTIALS; NERVE FIBERS, MYELINATED; ORGANOPLATINUM COMPOUNDS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RANA ESCULENTA; RANVIER'S NODES; SODIUM CHANNEL BLOCKERS; SODIUM CHANNELS;

ANURA;

EID: 33845275162     PISSN: 02315882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. + channel kinetics on rat sensory neurons. Eur. J. Pharmacol. 406, 25-32
2. Benoit E. (1993): Interactions of guanidine and a related compound with potassium channels in frog myelinated nerve fibre. Recept. Channels 1, 181-191
3. Benoit E., Corbier A., Dubois J. M. (1985): Evidence for two transient sodium currents in the frog node of Ranvier. J. Physiol. (London) 361, 339-360
4. Cassidy J., Misset J. L. (2002): Oxaliplatin-related side effects: characteristics and management. Semin. Oncol. 29, 11-20
5. Chiu S. Y., Ritchie J. M. (1981a): Ionic and gating currents in mammalian myelinated nerve. Adv. Neurol. 31, 313-328
6. Chiu S. Y., Ritchie J. M. (1981b): Evidence for the presence of potassium channels in the paranodal region of acutely demyelinated mammalian single nerve fibres. J. Physiol. (London) 313, 415-437
7. Elinder F., Arhem P. (1998): The functional surface charge density of a fast K channel in the myelinated axon of Xenopus laevis. J. Membr. Biol. 165, 175-181
8. Extra J. M., Marty M., Brienza S., Misset J. L. (1998): Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol. 25, 13-22
9. Frankenhaeuser B., Huxley A. F. (1964): The action potential in the myelinated nerve of Xenopus laevis as computed on the basis of voltage clamp data. J. Physiol. (London) 171, 302-315
10. Gamelin L., Boisdron-Celle M., Delva R., Guerin-Meyer V., Ifrah N., Morel A., Gamelin E. (2004): Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 10, 4055-4061
11. Graham M. A., Lockwood G. F., Greenslade D., Brienza S., Bayssas M., Gamelin E. (2000): Clinical pharmacokinetics of oxaliplatin: a critical review. Clin. Cancer Res. 6, 1205-1218
12. Grolleau F., Gamelin L., Boisdron-Celle M., Lapied B., Pelhate M., Gamelin E. (2001): A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 85, 2293-2297
13. Grothey A. (2005): Clinical management of oxaliplatin-associated neurotoxicity. Clin. Colorectal Cancer 5, S38-46
14. Grothey A., Goldberg R. M. (2004): A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin. Pharmacother. 5, 2159-2170
15. Hille B. (1968): Charges and potentials at the nerve surface. Divalent ions and pH. J. Gen. Physiol. 51, 221-236
16. +-ATPase α1 subunit in the intracellular accumulation of cisplatin. Cancer Chemother. Pharmacol. 57, 84-90
17. Kweekel D. M., Gelderblom H., Guchelaar H. J. (2005). Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Rev. 31, 90-105
18. Lorusso P. M. (2000): Oxaliplatin in tumors other than colorectal cancer. Oncology 14, 33-37
19. McKeage M. J., Hsu T., Screnci D., Haddad G., Baguley B. C. (2001): Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br. J. Cancer 85, 1219-1225
20. Misset J. L., Bleiberg H., Sutherland W., Bekradda M., Cvitkovic E. (2000): Oxaliplatin clinical activity: a review. Crit. Rev. Oncol. Hematol. 35, 75-93
21. Neumcke B., Stämpfli R. (1984): Heterogeneity of external surface charges near sodium channels in the nodal membrane of frog nerve. Pflügers Arch. 401, 125-131
22. Nonner W. (1969): A new voltage clamp method for Ranvier nodes. Pflügers Arch. 309, 176-192
23. Schwarz J. R., Reid G., Bostock H. (1995): Action potentials and membrane currents in the human node of Ranvier. Pflügers Arch. 430, 283-292
24. Stämpfli R., Hille B. (1976): Electrophysiology of the peripheral myelinated nerve. In: Handbook of Frog Neurobiology (Eds. R. Llinas and W. Precht), pp. 3-32, Springer, Heidelberg
25. Zaniboni A., Meriggi F. (2005): The emerging role of oxaliplatin in the treatment of gastric cancer. J. Chemother. 17, 656-662